Astellas Pharma Gmbh

Yasuyuki Higashi

Akira Tanaka

Yutaka Nakajima

Takayuki Inoue

Hiroshi Sasaki

Shohei Shirakami

Koichiro Mukoyoshi

Fumie Takahashi

Keiko Hatanaka

Hisao Hamaguchi

Masataka Morita

Shigeki Kunikawa

Takashi Tojo

Takeshi Hondo

Kazuo Nakai

Hitoshi Sawada

Shozo Sakuma

Akira Okimoto

Tatsuya Sasakawa

The invention relates to compound of the formula (I) or its salt, wherein &#x2014;R, &#x2014;R, &#x2014;R, &#x2014;R, &#x2014;R, -M-, &#x2014;X&#x2014; and &#x2014;Y&#x2550; are as defined in the description, their use of as, medicament, the process for their preparation and use for the treatment of JAK3 mediated diseases. 

Heterocyclic Janus Kinase 3 inhibitors

The present invention provides a compound of formula (I) having an excellent JAK3 inhibition activity and being useful as an active ingredient of an agent for treating and/or preventing various immune diseases including autoimmune diseases inflammatory diseases, and allergic diseases. The compound according to the present invention has an inhibition activity against JAK3 and is thus useful as an active ingredient of an agent for treating or preventing diseases caused by undesirable cytokine signal transmission (e.g., rejection during organ/tissue transplantation, autoimmune diseases, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, Alzheimer's disease, and atherosclerotic disease), or diseases caused by abnormal cytokine signal transmission (e.g., cancer and leukemia). 

Heterocyclic janus kinase 3 inhibitors

An animal suitable as a model for an allergic disorder, wherein the animal is an immuno-modulated animal which has been sensitized with an antigen under a specific pathogen free environment such that when the animal displays allergy symptoms caused by the antigen.

Animal model for allergic disorders

Growing community of inventors

Tokyo, Japan

Yasuyuki Higashi